CD276 and neoplasm: Although the identities of its binding partners remain unclear, a wide range of B7-H3 expression has been reported in multiple tumor types, including non–small cell lung cancer (Carvajal-Hausdorf et al., 2019a), prostate cancer (Yuan et al., 2011), and renal cell cancer (Crispen et al., 2008).